Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending January 13, 2004. The report serves to disclose changes in directors' interests in the company's Ordinary Shares and transactions related to employee benefit trusts.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. The document focuses exclusively on share transaction details rather than consolidated financial performance.
Material Changes
The filing details specific share acquisitions occurring on January 12, 2004:
- Director Acquisition: Mr. J.D. Coombe acquired 20 Ordinary Shares (10 via personal contribution and 10 via company matching) under the ShareReward Plan at a price of £12.18 per share.
- Employee Benefit Trust Purchases: The SmithKline Beecham Employee Benefit Trust purchased 1,330 shares for the Bonus Investment Plan at £12.18 per share and 4,465 shares for the Annual Investment Plan at £12.17 per share.
Guidance, Outlook, and Risks
The filing text does not provide a clear value for guidance, outlook, management commentary, risks, contingencies, or unusual items. The document is a routine disclosure of director and trust shareholdings.
Key Facts for Investor Verification
- Verify the total number of shares held by Director J.D. Coombe following the January 12, 2004 acquisition.
- Confirm the pricing consistency of the share purchases (£12.17–£12.18) against the market price on January 12, 2004.
- Review the terms of the ShareReward Plan and the SmithKline Beecham Employee Benefit Trust to understand the scope of director interests.